1 Product identity
Ingredient risk
Contains a high-risk ingredient
Adreno-Lyph-Para
BrandNutri-West→Other Combinations Tablet or Pill 13 ingredients 1 high-risk DSLD #27537Net contents: 60 Tablet(s)
Target: Adults and Children 4 years and above
DSLD entry: 2013-11-25
2 Ingredients (13)
IngredientGroupSafety
Bioflavonoid ComplexBlend (Combination)—
MethionineMETHIONINE—
Tissue concentratesBlend (non-nutrient/non-botanical)—
AdrenalAdrenals—
PituitaryPituitary—
ParotidParotid—
Ingredient amounts require the full DSLD label. View full label at NIH DSLD →
⛔ High-risk ingredient — documented serious harm
Inositol — GDM prevention — 4 g/day from first trimester in high-risk women [2]
3 Safety cross-reference
Vitamin C — Generally Safe
⚠ GI distress at high doses
⚠ Kidney stones risk >1g/day
Calcium — Conditionally Safe
⚠ Cardiovascular risk debated >1,000 mg/day
⚠ Kidney stones
Niacin — Conditionally Safe
⚠ Flushing at >50 mg
⚠ Hepatotoxicity at high doses
Folate — Conditionally Safe
⚠ May mask B12 deficiency
⚠ Colorectal cancer risk debated
Pantothenic Acid — Limited Evidence
⚠ Diarrhea at very high doses
Choline — Generally Safe
⚠ Fishy odor at high doses
Inositol — High risk
⚠ GI disturbance at high doses (>12 g)
⚠ May lower blood glucose
4 Label claims
• All Other
5 Data source
DSLD ID27537
Full labelView at NIH DSLD →
SourceOffice of Dietary Supplements, NIH
Market statusOn market
Entry date2013-11-25
6 More from Nutri-West
View Nutri-West Safety Scorecard → 186 products
#1 - AD#2 - CFAdreno - Lyph - SymAdreno-Lyph 80Adreno-Lyph-160Adreno-Lyph-Plus7 Cite this page
Vancouver
Pkhakadze G. Adreno-Lyph-Para — product analysis [Internet]. Tbilisi: Public Health Institute of Georgia; 2026 [cited 2026 Aug 25]. Available from: https://supplement.ge/products/adreno-lyph-para-27537/
CC BY 4.0. Product data from NIH DSLD; safety analysis by SupplementIndex.
GP
Analyzed by SupplementIndex
PHIG · Editor-in-Chief: Prof. Giorgi Pkhakadze, MD, MPH, PhD
Product data sourced from the NIH Dietary Supplement Label Database (DSLD). Safety cross-referencing by SupplementIndex. This analysis is for informational purposes only. For corrections: info@accreditation.ge.
Publisher: PHIG
Publisher: PHIG